Download PDF
Semin Respir Crit Care Med 2013; 34(06): 837-844
DOI: 10.1055/s-0033-1358553
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Salvage Therapy beyond Targeted Therapy in Lung Adenocarcinoma

James Chung-man Ho
1   Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China
,
Terence Chi-chun Tam
1   Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China
,
Sze-kwan Lam
1   Division of Respiratory Medicine, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China
› Author Affiliations
Further Information

Publication History

Publication Date:
20 November 2013 (online)

    Permissions and Reprints

Abstract

Targeted therapy in lung adenocarcinoma has evolved rapidly over the last few years, especially in the application of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs). Although many patients with advanced EGFR-mutated or ALK-rearranged lung adenocarcinoma do benefit from treatment with a specific TKI, the duration of disease control is notoriously short. Different patterns of disease progression have been recognized that may require distinct treatment approaches. Isolated progressive disease in the central nervous system requires additional local therapy (radiotherapy or surgery) and an exploratory pulsatile regimen of TKI. Oligoprogressive disease at extracranial sites, representing resistant tumor clones in isolated lesions, requires local ablative therapy (radiotherapy or surgery) and continuation of the existing TKI. Multifocal progressive disease is a key therapeutic challenge to overcome because of widespread acquired resistance due to heterogeneous mechanisms. It is now known that EGFR TKI–acquired resistance is mostly (50–60%) due to a single resistance mutation in exon 20 (T790M) and occasionally (5–10%) due to c-MET amplification. On the contrary, the acquired resistance mechanisms to ALK TKI appear more diverse. Specific therapeutic strategies are being developed to overcome various acquired resistance mechanisms and may further improve the overall prognosis of advanced lung adenocarcinoma with actionable driver mutations.

Keywords

targeted therapy - lung adenocarcinoma - acquired resistance - epidermal growth factor receptor - anaplastic lymphoma kinase
 

  • References

  • 1 Mok TS, Wu YL, Thongprasert S , et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361 (10) 947-957
    CrossrefPubMedGoogle Scholar
  • 2 Han JY, Park K, Kim SW , et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012; 30 (10) 1122-1128
    CrossrefPubMedGoogle Scholar
  • 3 Mitsudomi T, Morita S, Yatabe Y , et al; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11 (2) 121-128
    CrossrefPubMedGoogle Scholar
  • 4 Maemondo M, Inoue A, Kobayashi K , et al; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362 (25) 2380-2388
    CrossrefPubMedGoogle Scholar
  • 5 Zhou C, Wu YL, Chen G , et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12 (8) 735-742
    CrossrefPubMedGoogle Scholar
  • 6 Rosell R, Carcereny E, Gervais R , et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13 (3) 239-246
    CrossrefPubMedGoogle Scholar
  • 7 Soda M, Choi YL, Enomoto M , et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448 (7153) 561-566
    CrossrefPubMedGoogle Scholar
  • 8 Kwak EL, Bang YJ, Camidge DR , et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363 (18) 1693-1703
    CrossrefPubMedGoogle Scholar
  • 9 Camidge DR, Bang YJ, Kwak EL , et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13 (10) 1011-1019
    CrossrefPubMedGoogle Scholar
  • 10 Shaw AT, Kim DW, Nakagawa K , et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368 (25) 2385-2394
    CrossrefPubMedGoogle Scholar
  • 11 Eisenhauer EA, Therasse P, Bogaerts J , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (2) 228-247
    CrossrefPubMedGoogle Scholar
  • 12 Yang JJ, Chen HJ, Yan HH , et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer 2013; 79 (1) 33-39
    CrossrefPubMedGoogle Scholar
  • 13 Heon S, Yeap BY, Britt GJ , et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 2010; 16 (23) 5873-5882
    CrossrefPubMedGoogle Scholar
  • 14 Omuro AM, Kris MG, Miller VA , et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005; 103 (11) 2344-2348
    CrossrefPubMedGoogle Scholar
  • 15 Eichler AF, Kahle KT, Wang DL , et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro-oncol 2010; 12 (11) 1193-1199
    PubMedGoogle Scholar
  • 16 Chun SG, Choe KS, Iyengar P, Yordy JS, Timmerman RD. Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?. Cancer Biol Ther 2012; 13 (14) 1376-1383
    CrossrefPubMedGoogle Scholar
  • 17 Jackman DM, Holmes AJ, Lindeman N , et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006; 24 (27) 4517-4520
    CrossrefPubMedGoogle Scholar
  • 18 Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010; 99 (2) 283-286
    CrossrefPubMedGoogle Scholar
  • 19 Costa DB, Kobayashi S, Pandya SS , et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011; 29 (15) e443-e445
    CrossrefPubMedGoogle Scholar
  • 20 Katayama T, Shimizu J, Suda K , et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009; 4 (11) 1415-1419
    CrossrefPubMedGoogle Scholar
  • 21 Kuiper JL, Smit EF. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases—one with a remarkable thoracic response as well. Lung Cancer 2013; 80 (1) 102-105
    CrossrefPubMedGoogle Scholar
  • 22 Grommes C, Oxnard GR, Kris MG , et al. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro-oncol 2011; 13 (12) 1364-1369
    PubMedGoogle Scholar
  • 23 Weickhardt AJ, Scheier B, Burke JM , et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012; 7 (12) 1807-1814
    CrossrefPubMedGoogle Scholar
  • 24 Jackman D, Pao W, Riely GJ , et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010; 28 (2) 357-360
    CrossrefPubMedGoogle Scholar
  • 25 Pao W, Miller VA, Politi KA , et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2 (3) e73
    CrossrefPubMedGoogle Scholar
  • 26 Kosaka T, Yatabe Y, Endoh H , et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006; 12 (19) 5764-5769
    CrossrefPubMedGoogle Scholar
  • 27 Balak MN, Gong Y, Riely GJ , et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12 (21) 6494-6501
    CrossrefPubMedGoogle Scholar
  • 28 Bean J, Brennan C, Shih JY , et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104 (52) 20932-20937
    CrossrefPubMedGoogle Scholar
  • 29 Arcila ME, Oxnard GR, Nafa K , et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011; 17 (5) 1169-1180
    CrossrefPubMedGoogle Scholar
  • 30 Sequist LV, Waltman BA, Dias-Santagata D , et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3 (75) 75ra26
    CrossrefPubMedGoogle Scholar
  • 31 Yano S, Yamada T, Takeuchi S , et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011; 6 (12) 2011-2017
    CrossrefPubMedGoogle Scholar
  • 32 Yu HA, Arcila ME, Rekhtman N , et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19 (8) 2240-2247
    CrossrefPubMedGoogle Scholar
  • 33 Bean J, Riely GJ, Balak M , et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008; 14 (22) 7519-7525
    CrossrefPubMedGoogle Scholar
  • 34 Kobayashi S, Boggon TJ, Dayaram T , et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352 (8) 786-792
    CrossrefPubMedGoogle Scholar
  • 35 Yun CH, Mengwasser KE, Toms AV , et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008; 105 (6) 2070-2075
    CrossrefPubMedGoogle Scholar
  • 36 Oh JE, An CH, Yoo NJ, Lee SH. Detection of low-level EGFR T790M mutation in lung cancer tissues. APMIS 2011; 119 (7) 403-411
    CrossrefPubMedGoogle Scholar
  • 37 Oxnard GR, Arcila ME, Sima CS , et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011; 17 (6) 1616-1622
    CrossrefPubMedGoogle Scholar
  • 38 Uramoto H, Yano S, Tanaka F. T790M is associated with a favorable prognosis in Japanese patients treated with an EGFR-TKI. Lung Cancer 2012; 76 (1) 129-130
    CrossrefPubMedGoogle Scholar
  • 39 Engelman JA, Zejnullahu K, Mitsudomi T , et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316 (5827) 1039-1043
    CrossrefPubMedGoogle Scholar
  • 40 Doebele RC, Pilling AB, Aisner DL , et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012; 18 (5) 1472-1482
    CrossrefPubMedGoogle Scholar
  • 41 Katayama R, Shaw AT, Khan TM , et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012; 4 (120) 120ra17 . doi:10.1126/scitranslmed.3003316. Epub 2012 Jan 25
    CrossrefPubMedGoogle Scholar
  • 42 Kim S, Kim TM, Kim DW , et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol 2013; 8 (4) 415-422
    CrossrefPubMedGoogle Scholar
  • 43 Li D, Ambrogio L, Shimamura T , et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008; 27 (34) 4702-4711
    CrossrefPubMedGoogle Scholar
  • 44 Miller VA, Hirsh V, Cadranel J , et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13 (5) 528-538
    CrossrefPubMedGoogle Scholar
  • 45 Engelman JA, Zejnullahu K, Gale CM , et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67 (24) 11924-11932
    CrossrefPubMedGoogle Scholar
  • 46 Gonzales AJ, Hook KE, Althaus IW , et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008; 7 (7) 1880-1889
    CrossrefPubMedGoogle Scholar
  • 47 Campbell ARK, Camidge DR , et al. PF-00299804 (PF229) patient-reported outcomes and efficacy in adenocarcinoma and nonadeno non-small cell lung cancer: a phase 2 trial in advanced NSCLC after failure of chemotherapy and erlotinib [abstract]. J Clin Oncol 2010; 28 (15 Suppl): 7596
    PubMedGoogle Scholar
  • 48 Zhou W, Ercan D, Chen L , et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009; 462 (7276) 1070-1074
    CrossrefPubMedGoogle Scholar
  • 49 Janjigian YY SE, Horn L , et al. Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors [abstract]. Ann Oncol 2012; 23 (Suppl. 09) ix401
    CrossrefPubMedGoogle Scholar
  • 50 Spigel DR ET, Ramlau R , et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC [abstract]. J Clin Oncol 2011; 29 (15, Suppl): 7505
    PubMedGoogle Scholar
  • 51 Giaccone G, Herbst RS, Manegold C , et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1. J Clin Oncol 2004; 22 (5) 777-784
    CrossrefPubMedGoogle Scholar
  • 52 Herbst RS, Giaccone G, Schiller JH , et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2. J Clin Oncol 2004; 22 (5) 785-794
    CrossrefPubMedGoogle Scholar
  • 53 Perez-Soler R. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res 2004; 10 (12 Pt 2) 4238s-4240s
    CrossrefPubMedGoogle Scholar
  • 54 Marsilje TH, Pei W, Chen B , et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 2013; Jun 26. [Epub ahead of print]
    PubMedGoogle Scholar
  • 55 Mehra RCD, Sharma S , et al. First-in-human phase 1 study of the ALK inhibitor LDK378 in ALK+ solid tumors [abstract]. J Clin Oncol 2012; 30 (15, Suppl): 3007
    PubMedGoogle Scholar
  • 56 Katayama R, Khan TM, Benes C , et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A 2011; 108 (18) 7535-7540
    CrossrefPubMedGoogle Scholar
  • 57 Sequist LV, Gettinger S, Senzer NN , et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010; 28 (33) 4953-4960
    CrossrefPubMedGoogle Scholar